StockData
argenx SE logo

argenx SE (ARGX) stock

ARGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 19, 2026Score 5/30
$941.25−6.27 (-0.66%)

Close on Nov 18, 2026Market cap –P/E 48.1Yield –

argenx free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

For fiscal 2025 it was $679.03M. The highest annual figure on record is $679.03M in fiscal 2025.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$679.03M–
FY2024Dec 31, 2024-$84.55M–
FY2023Dec 31, 2023-$421.14M–
FY2022Dec 31, 2022-$863.64M–
FY2021Dec 31, 2021-$610.44M–
FY2020Dec 31, 2020-$399.53M-366.6%
FY2019Dec 31, 2019$149.83M–

More argenx figures

See a number that looks wrong?